NeOnc Technologies schedules FDA end-of-Phase 1 meeting for brain cancer drug NEO212
Bitget2026/09/28 12:02- NeOnc Technologies scheduled an in-person FDA End-of-Phase 1 meeting for NEO212 on Nov. 17, 2026.
- Phase 1 results were already reported; the company flagged durable disease control in two heavily pretreated brain cancer patients.
- Management framed the outcome as supportive of advancing NEO212 into Phase 2 and pursuing a registrational strategy.
- FDA feedback will guide a revised Phase 2 plan, including patient population and endpoints, with no assurance of accelerated approval.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI drops to near $89.00 as OPEC+ holds November targets
BUZZ - TSMC shares rise 3% after Elon Musk confirms negotiations on the TeraFab project
October 5th – Elon Musk confirmed discussions with TSMC (2330.TW), prompting a 3% increase in the company’s share price. The Taiwan Stock Exchange Weighted Index (.TWII) rose by 2.4%. Tesla (TELA.O) and SpaceX (SPCX.O) CEO Musk stated on Saturday via X platform that TSMC and his chip manufacturing project, Terafab, have discussed potential collaboration. In response to a post on X featuring a screenshot of an article titled “TSMC is exploring plans to cooperate with Elon Musk’s TeraFab,” Musk replied on Saturday: "It is only at the discussion stage for now, but something could result." TSMC’s share price has increased by 66% so far this year. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or lack needed context, Reuters does not guarantee the accuracy of the automated translated texts. They are provided merely for the convenience of readers. Reuters bears no responsibility for any damage or losses resulting from the use of the automated translation function.)
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Current Spread in Yield Basis Points Germany 3.475 % Australia 5.347 % 187.2 Belgium 4.339 % 86.4 Canada 3.944 % 46.9 Denmark 3.268 % -20.7 France 4.866 % 139.1 Italy 4.604 % 113.0 Japan 3.089 % -38.6 Netherlands 3.577 % 10.2 Spain 4.087 % 61.2 Sweden 3.146 % -32.9 U.K. 5.369 % 189.4 U.S. 5.256 % 178.1 Source: Tullett Prebon via FactSet (END) Dow Jones Newswires October 04, 2026 22:10 ET (02:10 GMT)
BoJ’s Uchida: AI has become a major focus among central banks, including at BoJ policy meetings
Crypto prices
More
